YBYehudit Birger

Yehudit Birger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yehudit Birger has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Shai Izraeli

    Felsenstein Research Institute, Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tiqva, Israel

    3 shared publications
  • Amir Giladi

    Department of Immunology, Weizmann Institute of Science, Rehovot

    1 shared publication
  • Angela Maria Savino

    Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Edmond and Lily Safra Children's hospital Chaim Sheba Medical Center, Tel Hashomer, Israel

    1 shared publication
  • Annat Raiter

    Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel; Tel Aviv University, Faculty of Medicine and Health Sciences, Tel Aviv, Israel; Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel

    1 shared publication
  • Arndt Borkhardt

    Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany

    1 shared publication
  • Arnon Nagler

    Division of Hematology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

    1 shared publication

Latest Publications

  • Open Access

    Galectin-3 secreted by triple-negative breast cancer cells regulates T cell function

    by Annat Raiter, Yael Barhum, Julia Lipovetsky, Chen Menachem, Sharona Elgavish, Shmuel Ruppo, Yehudit Birger, Shai Izraeli, Orna Steinberg-Shemer, Rinat Yerushalmi


  • Open Access

    Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency

    by Avigail Rein, Ifat Geron, Eitan Kugler, Hila Fishman, Eyal Gottlieb, Ifat Abramovich, Amir Giladi, Ido Amit, Roger Mulet-Lazaro, Ruud Delwel, et al.

    Mono-allelic germline disruptions of the transcription factor GATA2 result in a propensity for developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), affecting more than 85% of carriers. How a partial loss of GATA2 functionality enables leukemic transformation years later is unclear. This question has remained unsolved mainly due to the lack of informative models, as Gata2 heterozygote mice do not develop hematologic malignancies. Here we show that two different germline Gata2 mutations (TgErg/Gata2het and TgErg/Gata2L359V) accelerate AML in mice expressing the human hematopoietic stem cell regulator ERG. Analysis of Erg/Gata2het fetal liver and bone marrow-derived hematopoietic cells revealed a distinct pre-leukemic phenotype. This was characterized by enhanced transition from stem to progenitor state, increased proliferation, and a striking mitochondrial phenotype, consisting of highly expressed oxidative-phosphorylation-related gene sets, elevated oxygen consumption rates, and notably, markedly distorted mitochondrial morphology. Importantly, the same mitochondrial gene-expression signature was observed in human AML harboring GATA2 aberrations. Similar to the observations in mice, non-leukemic bone marrows from children with germline GATA2 mutation demonstrated marked mitochondrial abnormalities. Thus, we observed the tumor suppressive effects of GATA2 in two germline Gata2 genetic mouse models. As oncogenic mutations often accumulate with age, GATA2 deficiency-mediated priming of hematopoietic cells for oncogenic transformation may explain the earlier occurrence of MDS/AML in patients with GATA2 germline mutation. The mitochondrial phenotype is a potential therapeutic opportunity for the prevention of leukemic transformation in these patients.


  • Open Access

    An instructive role for IL7RA in the development of human B-cell precursor leukemia

    by Ifat Geron, Angela Maria Savino, Noa Tal, John Brown, Virginia Turati, Chela James, Jolanda Sarno, Yu Nee Lee, Avigail Rein Gil, Hila Fishman, et al.

    B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is preceded by a clinically silent pre-leukemia. Experimental models that authentically re-capitulate disease initiation and progression in human cells are lacking. We previously described activating mutations in interleukin 7 receptor alpha (IL7RA) that are associated with the poor-prognosis Philadelphia-like (Ph-like) subtype of BCP-ALL. Whether IL7RA signaling has a role in initiation of human BCP-ALL is unknown.IL7RA is essential for mouse B-cell development; however, patients with truncatingIL7RAgermline mutations develop normal mature B-cell populations. Herein, we explore the consequences of aberrant IL7RA signaling activation in human hematopoietic progenitors on malignant B-cell development.Transplantation of human cord-blood hematopoietic progenitors transduced with activated mutant IL7RA into NOD/LtSz-scid IL2Rγnullmice resulted in B-cell differentiation arrest with aberrant expression of CD34+and persistence of pro-B cells that survive despite failing to achieve productive rearrangement of immunoglobulin V(D)J gene segments. Activation of IL7RA signaling enhanced self-renewal and facilitated the development of a BCP-ALL in secondary transplanted mice. The development of leukemia was associated with spontaneous acquired deletions in CDKN2A/B and IKZF1 similar to what is observed in Ph-like BCP-ALL in humans. Single cell gene expression analysis suggested that pre-leukemic cells resided within a subpopulation of early B-cell precursors with CD34+CD10highCD19lowimmunophenotype.The development of a bona fide BCP-ALL from IL7RA transduced cells supports the hypothesis that aberrant activation of the IL7RA pathway in human B-cell lineage progenitors has an instructive role by creating a pre-leukemic state which is vulnerable to transformation. These are the first demonstrations of a role for IL7RA in human B-cell differentiation and of a de-novo Ph-like BCP-ALL development from normal human hematopoietic progenitorsin vivo.